Cargando…
The impact of orthopaedic research evidence on health financing in Australia
BACKGROUND: In Australia, approval by the Medical Services Advisory Committee (MSAC) is an important step in the implementation of new health technologies. The MSAC considers health technology assessments (HTA) when submitting a recommendation to the Minister of Health on a new technology’s suitabil...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930773/ https://www.ncbi.nlm.nih.gov/pubmed/29716606 http://dx.doi.org/10.1186/s12961-018-0314-0 |
_version_ | 1783319535519006720 |
---|---|
author | Hua, Martin Myers, Daniel Host, Lachlan |
author_facet | Hua, Martin Myers, Daniel Host, Lachlan |
author_sort | Hua, Martin |
collection | PubMed |
description | BACKGROUND: In Australia, approval by the Medical Services Advisory Committee (MSAC) is an important step in the implementation of new health technologies. The MSAC considers health technology assessments (HTA) when submitting a recommendation to the Minister of Health on a new technology’s suitability for public funding. Despite being such a critical tool in formulating policy, there has been little scrutiny on the impact of limited evidence on the performance of a national HTA agency’s mandate. We aim to determine the proportion of HTAs of orthopaedic technologies prepared for the MSAC that were supported by higher levels of evidence for effectiveness, and whether this affected the MSAC’s ability to conclude on efficacy. We also investigated whether the availability of higher level evidence affected the performance of cost-effectiveness analyses. METHODS: We performed a cohort study of all HTAs prepared for the MSAC from 1998 to 2017 with regards to new technologies in orthopaedic surgery. RESULTS: We identified seven HTAs encompassing nine orthopaedic technologies for inclusion. Higher levels of evidence were available for assessing the technology’s effectiveness in six out of the nine technologies. The results did not show a statistically significant relationship between the availability of higher level evidence and MSAC’s ability to make a clear conclusion on the assessment of effectiveness (P = 0.5). The proportion of HTAs where a cost-effectiveness analysis was performed was significantly higher (P < 0.05) when higher levels of evidence were available for the assessment of effectiveness. CONCLUSIONS: The results indicate that there is a paucity of high quality evidence in the formulation of health policy with regards to the implementation of new orthopaedic technologies in the public healthcare system. This represents an opportunity for strong leadership from surgeons to help develop the tools needed for effective clinical decision-making. |
format | Online Article Text |
id | pubmed-5930773 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-59307732018-05-09 The impact of orthopaedic research evidence on health financing in Australia Hua, Martin Myers, Daniel Host, Lachlan Health Res Policy Syst Research BACKGROUND: In Australia, approval by the Medical Services Advisory Committee (MSAC) is an important step in the implementation of new health technologies. The MSAC considers health technology assessments (HTA) when submitting a recommendation to the Minister of Health on a new technology’s suitability for public funding. Despite being such a critical tool in formulating policy, there has been little scrutiny on the impact of limited evidence on the performance of a national HTA agency’s mandate. We aim to determine the proportion of HTAs of orthopaedic technologies prepared for the MSAC that were supported by higher levels of evidence for effectiveness, and whether this affected the MSAC’s ability to conclude on efficacy. We also investigated whether the availability of higher level evidence affected the performance of cost-effectiveness analyses. METHODS: We performed a cohort study of all HTAs prepared for the MSAC from 1998 to 2017 with regards to new technologies in orthopaedic surgery. RESULTS: We identified seven HTAs encompassing nine orthopaedic technologies for inclusion. Higher levels of evidence were available for assessing the technology’s effectiveness in six out of the nine technologies. The results did not show a statistically significant relationship between the availability of higher level evidence and MSAC’s ability to make a clear conclusion on the assessment of effectiveness (P = 0.5). The proportion of HTAs where a cost-effectiveness analysis was performed was significantly higher (P < 0.05) when higher levels of evidence were available for the assessment of effectiveness. CONCLUSIONS: The results indicate that there is a paucity of high quality evidence in the formulation of health policy with regards to the implementation of new orthopaedic technologies in the public healthcare system. This represents an opportunity for strong leadership from surgeons to help develop the tools needed for effective clinical decision-making. BioMed Central 2018-05-02 /pmc/articles/PMC5930773/ /pubmed/29716606 http://dx.doi.org/10.1186/s12961-018-0314-0 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Hua, Martin Myers, Daniel Host, Lachlan The impact of orthopaedic research evidence on health financing in Australia |
title | The impact of orthopaedic research evidence on health financing in Australia |
title_full | The impact of orthopaedic research evidence on health financing in Australia |
title_fullStr | The impact of orthopaedic research evidence on health financing in Australia |
title_full_unstemmed | The impact of orthopaedic research evidence on health financing in Australia |
title_short | The impact of orthopaedic research evidence on health financing in Australia |
title_sort | impact of orthopaedic research evidence on health financing in australia |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930773/ https://www.ncbi.nlm.nih.gov/pubmed/29716606 http://dx.doi.org/10.1186/s12961-018-0314-0 |
work_keys_str_mv | AT huamartin theimpactoforthopaedicresearchevidenceonhealthfinancinginaustralia AT myersdaniel theimpactoforthopaedicresearchevidenceonhealthfinancinginaustralia AT hostlachlan theimpactoforthopaedicresearchevidenceonhealthfinancinginaustralia AT huamartin impactoforthopaedicresearchevidenceonhealthfinancinginaustralia AT myersdaniel impactoforthopaedicresearchevidenceonhealthfinancinginaustralia AT hostlachlan impactoforthopaedicresearchevidenceonhealthfinancinginaustralia |